| Expression pattern: |
UP |
| Associated gene: |
hnRNPA2B1, Yin Yang 1, YY1, Prospero homeobox 1, PROX1 |
| Associated microRNA: |
- |
| Biological function: |
Promotes lymphangiogenesis, lymphatic (lymph node) metastasis, and remodeling of the LN microenvironment in prostate cancer. |
| Molecular mechanism: |
circPDLIM5 is selectively packaged into EVs by hnRNPA2B1, delivered into HLECs, translocates to nuclei, binds YY1, and recruits YY1 to the PROX1 promoter to increase PROX1 transcription, promoting lymphangiogenesis and LN metastasis independent of VEGF-C. |
| Biological pathway or process: |
lymphangiogenesis (promotes); metastasis (promotes); migration (promotes); ceRNA regulation (other) |
| Detected method: |
Q
H
S
|
| Validation methods: |
RNA-seq; RT-qPCR; RNase R Treatment; Sanger Sequencing; divergent primers PCR; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; ISH (In Situ Hybridization); Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; ChIP / ChIP-seq; In Vivo Animal Model; IHC (Immunohistochemistry); Western Blot; Transfection; Tube Formation Assay; Transwell Assay; Luciferase Reporter Assay; Bioinformatics Analysis; ROC Analysis; Survival Analysis |
| Clinical significance: |
Urinary and serum EVs-circPDLIM5 discriminate LN-metastatic PCa and high levels are associated with poor radiographic progression-free survival (PFS); independent prognostic factor for PFS. |
| Description: |
circPDLIM5 (hsa_circ_0004028), derived from PDLIM5, is upregulated in LN-positive prostate cancer tissues and in urinary/serum EVs. It is packaged into EVs via hnRNPA2B1 and delivered to HLECs, where it binds YY1 and promotes PROX1 transcription, enhancing lymphangiogenesis and lymph node metastasis in a VEGF-C-independent manner; high EV circPDLIM5 levels indicate LN metastasis and poor PFS. |
| Confidence score: |
0.8981 |